CDC25B and hepatocellular carcinoma: In this study, the EDU experiment proved that the proliferation and differentiation ability of HCC cell lines decreased significantly after the knockdown of CDC25B, and drug sensitivity analysis suggested that the overexpression of CDC25B could reduce the sensitivity of some chemotherapeutic drugs, so we judged that CDC25B-selective inhibitors could also benefit HCC patients.